
Opinion|Videos|July 29, 2024
ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma
Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Discuss the emerging data presented at ASCO 2024 on the phase 1 study of IMC-F106C (brenetafusp), a PRAME x CD3 ImmTAC bispecific protein in post-checkpoint cutaneous melanoma. (
Abstract )
1. What was the objective of this study?
2. How was this study designed/what methodology was used?
3. What results were presented?
i. Patient population: N=46
A. Prior therapy: 100% anti-PD1, 88% anti-CTLA4, 25% BRAF/MEK inhibitors
ii. Primary objectives:
A. Safety
B. Selection of recommended dose
iii. Secondary objectives:
A. Efficacy
B. ctDNA response
- Please provide your key takeaways from this study. How might a PRAME x CD3 bispecific product impact the management of melanoma in the future?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

Obinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.

Infectious disease and urology clinicians described unclear treatment goals, infusion limits, and access barriers for newer UTI agents.

New ACACIA-HCM analyses at HCMS 2026 add imaging and quality-of-life data as Cytokinetics readies an FDA filing in nonobstructive HCM.

An oral SERD plus everolimus cut the risk of progression or death by 62% in ESR1-mutated advanced breast cancer.

New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.

Phase 3 OASIZ-301 data at ACR 2026 show dazodalibep lowered systemic activity in Sjögren disease, with dryness gains at the every-4-weeks dose.
Advertisement
Advertisement
Trending on AJMC
1
Emerging Threats to Cell and Gene Therapy Access
2
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
3
FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer
4
FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR
5

